HeartBeam Inc. (NASDAQ: BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai to accelerate the joint development and validation of next-generation AI-ECG algorithms. This partnership combines HeartBeam's patented ECG platform, which captures the heart's electrical activity from three non-coplanar dimensions, with Mount Sinai's clinically annotated 12-lead ECG datasets and artificial intelligence expertise to advance AI-driven cardiac monitoring.
The collaboration will leverage longitudinal, high-fidelity synthesized 12-lead ECG data collected from patients in home settings alongside Mount Sinai's clinical data resources. This approach aims to accelerate the training and validation of AI models designed to support personalized cardiac insights, expand potential clinical indications, and enable broader applications in preventive cardiology, chronic disease management, and remote patient monitoring. The partnership represents a significant step toward making sophisticated cardiac monitoring more accessible outside traditional medical facilities.
HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of medical facilities, potentially redefining the future of cardiac health management.
The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. HeartBeam holds over 20 issued patents related to technology enablement. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT. For details on the intended use of its technology, refer to the company's Cleared Indications for Use at https://www.heartbeam.com/indications.
This collaboration has significant implications for the healthcare industry and patients worldwide. By combining advanced AI capabilities with portable ECG technology, the partnership could enable earlier detection of cardiac conditions, more personalized treatment approaches, and improved management of chronic heart diseases. The ability to monitor cardiac health remotely could reduce hospital visits, lower healthcare costs, and improve outcomes for patients with cardiovascular conditions. As cardiovascular disease remains a leading cause of death globally, advancements in remote monitoring technology could have substantial public health impact by making cardiac care more proactive and accessible.
